Amgen Inc.
AMGN Healthcare Drug Manufacturers - General NASDAQ
$385.70
$-2.46 (-0.63%)
Open: $386.61 | High: $391.29 | Low: $381.89 | Prev Close: $388.16
Market Cap: $207.92B
Volume: 2.5M | Avg: 2.9M
Last updated: March 03, 2026 at 10:00 AMFeatured In
This stock appears in the following dashboards:
Investment Rating
Neutral
Overall Score: 60/100
Rating Breakdown:
Stock Score Analysis
Stock Score: 582
Comprehensive Quality Assessment
Component Breakdown:
Valuation Metrics
| P/E Ratio | 27.10 |
| P/B Ratio | 24.01 |
| P/S Ratio | 5.65 |
| EPS | $14.23 |
| Beta | 0.47 |
| Shares Outstanding | 539.07M |
| 52-Week High | $391.29 |
| 52-Week Low | $261.43 |
| SMA 50 | $347.83 |
| SMA 200 | $309.73 |
| Dividend Yield | 2.50% |
| Annual Dividend | $9.66 |
| Next Earnings | April 30, 2026 09:00 PM ET |
Financial Ratios
| Gross Margin | 70.5% |
| Operating Margin | 28.0% |
| Net Margin | 21.0% |
| ROE | 96.7% |
| ROA | 8.5% |
| Debt/Equity | 6.31 |
| Current Ratio | 1.14 |
| Quick Ratio | 0.90 |
Balance Sheet
| Total Assets | $90.59B |
| Total Liabilities | $81.93B |
| Total Equity | $8.66B |
|
|
|
| Cash | $9.13B |
| Total Debt | $54.60B |
| Net Debt | $45.48B |
Income Statement
| Revenue | $36.74B |
| Gross Profit | $26.01B |
| Operating Income | $10.68B |
| Net Income | $7.71B |
|
|
|
| EBITDA | $15.84B |
| Revenue/Share | $68.22 |
Cash Flow
| Operating CF | $9.96B |
| CapEx | $1.86B |
| Free Cash Flow | $8.10B |
|
|
|
| Book Value/Share | $16.06 |
| Tangible Book/Share | $-59.92 |
| Equity/Share | $16.06 |
Technical Indicators
| RSI (14) | 67.16 Neutral |
| MACD |
11.79
Signal: 11.17
|
| Volatility | 31.98% |
| Trading Signal | Bullish |
Performance & Returns
| 1 Year | +39.83% |
| Sharpe Ratio | 1.54 Good |
| Volatility (Ann.) | 28.3% Moderate |
| AMGN (1Y) | +39.83% |
| S&P 500 (1Y) | +13.03% |
| Alpha (Excess Return) | +26.79% |
Sector Comparison (Healthcare)
| Metric | AMGN | Sector Avg | Percentile |
|---|---|---|---|
| P/E Ratio | 27.1 | 27.67 | 53% |
| P/B Ratio | 24.01 | -19.98 | 93% |
| ROE (%) | 96.65% | -11.14% | 94% |
| Net Margin (%) | 20.97% | 9.09% | 77% |
| Stock Score | 582 | 543.0 | 66% |
| 1Y Return (%) | +39.83 % | +7.52 % | 87% |
📊 Historical Price Analysis (Last 200 Days)
Loading chart...
Technical Analysis
| Ticker | Close | SMA 5 | SMA 8 | SMA 13 | SMA 50 | SMA 200 | RSI (14) | MACD | Volatility (%) | Volume | Signal | SMA Decision |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AMGN | $385.70 | $382.53 | $380.32 | $376.87 | $345.26 | $308.35 | 67.16 | 11.79 | 31.98% | 2495391 | Strong Long | Bullish Stack |
Candlestick Patterns
There wasn't any recognizable pattern for the AMGN stock
News Sentiment
| 📊 Ticker | 📰 Headline | 💭 Sentiment | 📡 Source | 🔗 URL |
|---|---|---|---|---|
| AMGN | Amgen: MariTide And Osteoporosis Sales Fuel The Rally | Neutral | seekingalpha.com | Read More |
| AMGN | Josh Brown: Biotech growth stocks immune to disruption risk | Positive | 247wallst.com | Read More |
| AMGN | Amgen Inc. (AMGN) Presents at Leerink Global Healthcare Conference 2026 Transcript | Neutral | seekingalpha.com | Read More |
| AMGN | Gilead Gets a Buy, Amgen a Hold and ORIC a Vote of Confidence: Wall Street's Latest Biopharma Calls Explained | Neutral | 247wallst.com | Read More |
| AMGN | Here Are Tuesday’s Top Wall Street Analyst Research Calls: AT&T, Amgen, CrowdStrike, Gilead, Hims & Hers, Intuit, Lowe’s, Qualcomm, Rivian, Strategy and More | Neutral | 247wallst.com | Read More |
Recent Insider Trading
No recent insider trading data available for AMGN
Company Information
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
| CEO | Robert A. Bradway |
| Employees | 28000 |
| Country | US |
| IPO Date | 1983-06-17 |
| Exchange | NASDAQ |
| Website | https://www.amgen.com |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
Similar Stocks (Healthcare - Drug Manufacturers - General)
Rating Metrics Explained
DCF Score (Discounted Cash Flow)
Measures the intrinsic value of the stock based on projected future cash flows. A higher score indicates the stock is undervalued relative to its DCF valuation.
ROE Score (Return on Equity)
Evaluates how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better profitability and management effectiveness.
ROA Score (Return on Assets)
Measures how efficiently a company uses its assets to generate profit. A higher ROA means better asset utilization and operational efficiency.
D/E Score (Debt-to-Equity)
Assesses the company's financial leverage and risk. Lower debt-to-equity ratios indicate less financial risk and better balance sheet health.
P/E Score (Price-to-Earnings)
Compares stock price to earnings per share. A lower P/E ratio may indicate the stock is undervalued, while a higher ratio could suggest overvaluation or growth expectations.
P/B Score (Price-to-Book)
Compares market price to book value per share. Lower P/B ratios may indicate undervaluation relative to the company's net asset value.
Rating Recommendations:
Each metric is scored on a scale of 1-5, where the scores are determined by comparing the company's performance against industry benchmarks and historical data:
-
Strong Buy (5/5): Excellent score - strong positive indicator
- The metric significantly outperforms industry averages (top 20% of companies)
- Indicates exceptional financial health or attractive valuation in that category
-
Buy (4/5): Good score - positive indicator
- Above-average performance (top 40% of companies)
- Shows strong fundamentals with room for improvement
-
Neutral (3/5): Average score - neutral indicator
- Performance in line with industry median (middle 20%)
- Neither significantly positive nor negative signal
-
Sell (2/5): Below average - negative indicator
- Below-average performance (bottom 40% of companies)
- Suggests weakness in this particular metric
-
Strong Sell (1/5): Poor score - strong negative indicator
- Significantly underperforms industry (bottom 20%)
- Indicates potential risk or overvaluation in that category